Table 1 Included studies.

From: Comparison of luteal support protocols in fresh IVF/ICSI cycles: a network meta-analysis

Author et al., year

Country

Time period of study

Sample Size (post-drop outs)

Protocol for IVF (Compound, dose, duration)

Treatments examined

Treatment 1

Treatment 2

Treatment 3

Treatment 4

Gawron et al.25

Poland

2015–2016

170

Standard Long GnRH Agonist (35%); Standard Short GnRH antagonist (65%)

OPVP (21) vs. SCPVP (22)

T20: Duphaston, O, 30 mg, OPU till 12 weeks + Crinone 8%, PV, 90 mg, OPU till 12 week, 92

T21: Prolutex, SC, 25 mg, OPU till 12 weeks + Crinone 8%, PV, 90 mg, OPU till 12 week, 78

N/A

N/A

Kao et al.26

Taiwan

2019–2022

65

Standard Long GnRH Agonist (18.4%); Standard Short GnRH antagonist (81.6%)

SCP (2) vs. VP (3)

T2: Prolutex, SC, 25 mg, OPU + 2 till 7 weeks, 33

T3: Crinone 8%, PV, 90 mg, OPU + 2 till 7 week, 32

N/A

N/A

Razieh et al.27

Iran

Not stated

180

Standard Short GnRH antagonist (100%)

VPSCGNRH (14) vs Placebo (1)

T1: Placebo, 90

T14:Cyclogest, PV, 800 mg, OPU till 11 weeks + Decapeptyl, SC, 0.1 mg once off D3 post ET, 90

N/A

N/A

Iwase et al.28

Japan

1993–2003

40

Standard Short GnRH antagonist (100%)

IMP (6) vs OP (10)

T6: Progesterone, IM, 25 mg, from ET till D6 and 50 mg from D7-14, 20

T10: Chormadione acetate 12 mg, O, ET till 2 weeks, 20

N/A

N/A

Moini et al.29

Iran

2016 to 2018

80

Standard Long GnRH Agonist

SCP (2) vs VP (3)

T2: Prolutex, SC, 50 mg, OPU till 10 weeks, 40

T3: Cyclogest, PV, 400 mg, OPU till 10 weeks, 40

N/A

N/A

Madkour et al.30

Egypt

2011 to 2013

220

Standard Short GnRH antagonist

VP (3) vs VPOE (T5)

T3: Crinone 8%, PV, 180 mg, OPU till 12 weeks, 110

T5: Progyluton, PV, 4 mg, OPU to 7 weeks and Crinone 8%, PV, 180 mg, OPU till 12 weeks, 110

N/A

N/A

Kara et al.31

Turkey

2011 to 2013

208

Microdose flare protocol

VP (3) vs VPDHEA (18)

T3: Crinone 8%, PV, 90 mg BD, OPU till 12 weeks, 104

T18: Crinone 8%, PV, 90 mg BD, OPU till 12 weeks and DHEA, O, 75 mg, OPU till 12 weeks,104

N/A

N/A

Serna et al.32

Spain

Not stated

160

Standard Long GnRH Agonist

VP (3) vs VPPE (7)

Progeffik, PV, 400 mg, OPU till 10 week, 81

Progeffik, PV, 400 mg, OPU till 10 week and E2 patch Estraderm, 200 microgr, ET to 11 week, 79

N/A

N/A

Fatemi et al.33

Belgium

2004 to 2005

201

Standard Long GnRH Agonist

VP (3) vs VPOE (T5)

Utrogestan, PV, 600 mg, OPU + 1 to 7 week, 100

Utrogestan, PV, 600 mg, OPU + 1 to 7 week and Progynova, O, 4 mg, OPU + 1 to 7 week, 101

N/A

N/A

Kleinstein et al.34

Germany

1999 to 2001

212

Standard Long GnRH Agonist

VP (3) Tablet vs. gel (gel incl)

Crinone 8%, PV, 270 mg, OPU till 12 week, 212

Utrogestan, PV, 600 mg, OPU till 12 week,, 218

N/A

N/A

Zegers-Hochschild et al.35

Brazil

Not stated

505

Standard Long GnRH Agonist

VP (3) vs. IMP (6)

Vaginal ring, PV, 1 g, OPU to 5 weeks, 243

Progesterone, IM, 50 mg, OPU till 5 week, 262

N/A

N/A

Andersen et al.36

Denmark

1999 to 2003

153

Standard Long GnRH Agonist

VP (3) early W2 vs W5 withrawal

Progestan, PV, 600 mg, OPU till 5 week, 153

N/A

N/A

N/A

Artini et al.37

Italy

Not stated

176

Standard Long GnRH Agonist

Placebo (1) vs. VP (3) vs. IMP (6) vs IMHCG (9)

T1: Placebo, 44

T3: Miconised Progesterone, PV, 100 mg, OPU till 2 weeks, 44

T6: Natural progesterone, IM, 50 mg, OPU to 2 weeks, 44

T9: Profasi, IM, 2000 IU, OPU to 2 weeks, 44

Araujo et al.38

USA

Not stated

74

Standard Long GnRH Agonist

IMP (6) vs IMHCG (9)

T6: Progesterone, IM, 50 mg, OPU till 4 weeks, 37

T9: hCG, IM, 2000 IU on 3,6,9,12 post OPU, OPU till 4 weeks, 37

N/A

N/A

Griesinger et al.39

Australia, Belgium, China, Germany, Hong Kong, India, Russia, Singapore, Thailand and Ukraine

2015 to 2017

971

Standard Long GnRH Agonist and short GnRH antagonist (%, unknown)

VP (3) vs. OP (10)

T3: Crinone 8%, PV, 90 mg, OPU till 12 week, 481

T10: Duphaston, O, 30 mg, OPU till 12 weeks, 490

N/A

N/A

Goudge et al.40

USA

2005 to 2007

46

Standard Long GnRH Agonist and short GnRH antagonist

IMP (6)

T6: Progesterone, IM, 200 mg, OPU till 6 week, 46

N/A

N/A

N/A

Kohls et al.41

Spain

2009 to 2010

110

Standard short GnRH antagonist

VP (3)

T3: Miconised Progesterone, PV, 400 mg, OPU till 8 week, 110

N/A

N/A

N/A

Kyrou et al.42

Belgium

2008 to 2010

100

Standard short GnRH antagonist

VP (3)

T3: Miconised Progesterone, 600 mg, OPU till 8 week, 100

N/A

N/A

N/A

Prietl et al.43

Germany

1989 to Not stated

120

CC (5)/hMG (52)/long GnRH (32) agonist

Placebo (1) vs. IMPIME (11)

T1: Placebo, 65

T11: 17a-hydroxyprogesterone caproate, IM, 1000 mg weekly, OPU till 12 week and oestradiol valerate, 20 mg weekly, OPU till 12 week, 55

N/A

N/A

Ceyhan et al.44

Turkey

2006

59

Standard Short GnRH Antagonist

VP (3) vs. VPPE (7)

T3: Progestan, PV, 600 mg, OPU till 8 week, 29

T7: Progestan, PV, 600 mg, OPU till 8 week and Estrogen, Patch, 100 mcg, OPU till 8 week, 30

N/A

N/A

Farhi et al.45

Israel

1997 to 1998

271

Standard Long GnRH Agonist (214) and short GnRH antagonist (72)

IMVP (4) vs. IMPVPOE (12)

T4: Geston, IM, 150 mg, OPU + 1 till 6 week and Brand unknown, PV, 100 mg, OPU + 1 till 6 week, 142

T12: Geston, IM, 150 mg, OPU + 1 till 6 week and Brand unknown, PV, 100 mg, OPU + 1 till 6 week and Estrophem, O, 4 mg, OPU + 1 till 6 week, 129

N/A

N/A

Engmann et al.46

USA

2004 to 2005

166

Standard Long GnRH Agonist orstandard shor GnRh antagonist or microdose GnRH agonist

IMP (6) vs IMPPVE (13)

T6: Brand not stated, IM, 50 mg, OPU till 6 weeks, 82

T13: Brand not stated, IM, 50 mg, OPU till 6 weeks and micronised E2, PV, 4 mg, ET till week 6, 84

N/A

N/A

Belaisch-Allart et al.47

France

1988 to 1989

387

Standard Long GnRH Agonist (67%) or standard short GnRh antagonist (33%)

Placebo (1) vs IMHCG (9)

T1: Placebo, 194

T9: Pregnyl, IM, 1500 IU, OPU and 2 doses, 193

N/A

N/A

Kupferminc et al.48

Israel

1988 to 1989

156

Standard Long GnRH Agonist

Placebo (1) vs IMHCG (9) OP (10)

T1: Placebo, 51

T9: hCG, IM, 2500 IU on 3,6,10, ET till 2 weeks, 51

T10: Duphaston, O, 30 mg, ET to 2 weeks, 54

 

Aghahosseini et al.49

Iran

2008 to 2009

118

Standard Long GnRH Agonist

VP (3) vs. VPOE (5)

T3: Cyclogest, PV, 400 mg, OPU till 12 weeks, 55

T5: Cyclogest, PV, 400 mg, OPU till 12 weeks and Estradiol, O, 4 mg, OPU till 12 weeks, 53

N/A

N/A

Lin et al.50

China

2010 to 2011

402

Standard Long GnRH Agonist and short GnRH antagonist

IMP (6) vs. IMPOE (8)

T6: Progesterone oil, IM, 240 mg, OPU till 2 week, 200

T8: Progesterone oil, IM, 240 mg, OPU till 2 weeks and Estradiol valereate, O, 6 mg OD, OPU till 2 weeks, 202

N/A

N/A

Yanushpolsky51

USA

Not stated

407

Standard Short GnRH antagonist

VP (3) vs. IMP (6)

T3: Crinone 8%, 90 mg, PV, dose, OPU to 10 week, 206

T6: Progesterone, IM, 50 mg, OPU to 10 week, 201

N/A

N/A

Elgindy et al.52

Egypt

2004 to 2006

270

Standard Short GnRH antagonist

IMP (6) vs. IMPOE (8) vs. IMPPVE (13)

T6: Gestone, IM, 100 mg, ET to 6 week, 90

T8: Gestone, IM, 100 mg, ET to 6 week and Cycloprogynova, O, 6 mg, ET to 6 week, 90

T13:Gestone, IM, 100 mg, ET to 6 week and Cycloprogynova, PV, 6 mg, ET to 6 week, 90

N/A

Isik et al.53

Turkey

2005

159

Standard Short GnRH antagonist

VP (3) vs VPSCGNRH (14)

T3: Progestan, PV, 600 mg, OPU till 2 weeks, 80

T14: Progestan, PV, 600 mg, OPU till 2 weeks and Leuprolide acetate, SC, 0.5 mg once off D6 post ET, 74

N/A

N/A

Yildiz et al.54

Turkey

2008 to 2010

279

Standard Long GnRH Agonist

VPOE (5) vs. VPOESCGNRH (15)

T5: Progestan, O, 600 mg, OPU to 2 weeks and Estrofem, O, 4 mg, OPU to 2 weeks, 95

T15: Progestan, PV, 600 mg OD, OPU to 2 weeks and Estrofem, O, 4 mg OD, OPU to 2 weeks and leuprolide acetate, SC, 1/2 mg mg once off 3D post ET, 100

N/A

N/A

Dal Prato et al.55

Italy

2001 to 2004

412

Standard Long GnRH Agonist

VP (3) vs IMP (6)

T3: Crinone 8%, PV, 90 mg/180 mg, OPU + 1 till 5 week, 274

T6: Prontogest, IM, 50 mg, OPU + 1 till 5 week, 138

N/A

N/A

Propst et al.56

USA

1998 to 1999

201

Standard Long GnRH Agonist

VP (3) vs IMP (6)

T3: : Crinone 8%, PV, 90 mg, OPU till 10 weeks, 102

T6: Progesterone, IM, 50 mg, OPU till 10 weeks, 99

N/A

N/A

Chakravarty et al.57

India

2002 to 2003

430

Standard Long GnRH Agonist

VP (3) vs oP (10)

T3: Utrogestan, PV, 200 mg, ET + 1 till 2 weeks, 32

T10: Dydrogesterone, O, 20 mg, ET till 12 weeks, 79

N/A

N/A

Friedler et al.58

Israel

Not stated

64

Standard Long GnRH Agonist

VP (3) vs OP (10)

T3: Utrogestan, PV, 200 mg, ET + 1 till 2 weeks, 32

T10: Utrogestan, O, 800 mg, ET + 1 till 2 weeks, 32

N/A

N/A

Pouly et al.59

Belgium

Not stated

283

Standard Long GnRH Agonist

VP (3) vs OP (10)

T3: Crinone 8%, PV, 90 mg, ET till 13 weeks,139

T10: Utrogestan, O, 300 mg, ET till 13 weeks, 144

N/A

N/A

Salehpour et al.60

Iran

2014 to 2015

210

Standard Long GnRH Agonist (107) and short GnRH antagonist (103)

VP (3) vs OP (10)

T3: Cyclogest, PV, 800 mg, OPU till 12 weeks, 114

T10: Duphaston, O, 40 mg, OPU till 12 weeks, 96

N/A

N/A

Bergh et al.61

Denmark

2006 to 2010

1983

Standard Long GnRH Agonist

VP (3)

T3: Gel/Tablets, PV, 200 mg/600 mg/ 90 mg (gel)OPU to 5 weeks, 1983

N/A

N/A

N/A

Doody et al.62

USA

2005 to 2008

1211

Standard Long GnRH Agonist

VP (3)

T3: Gel/Tablets, PV, 200 mg/600 mg/ 90 mg (gel), OPU to 10 weeks, 1211

N/A

N/A

N/A

Tay et al.63

UK

1999 to 2000

161

Standard Long GnRH Agonist

VP (3) vs PRP (16) SCHCG (17)

T3: Crinone/Utrogestan, PV, 90 mg (gel), 200 mg/400 mg/600 mg (tablets), OPU to 2 weeks, 91

T16: Cyclogest, PR, 400 mg, OPU till 2 weeks, 35

T17: hCG, SC, 1500 IU, OPU + 2 and OPU + 7, twice off to 2 weeks , 35

N/A

Abate et al.64

Italy

1997 to 1998

156

Standard Long GnRH Agonist

PLACEBO (1) vs. VP (3) vs. IMP (6)

T1: placebo, 52

T3: Progesterone gel, PV, 90 mg OD, ET + 1 till 2 weeks, 52

T6: Progesterone, IM, 50 mg, ET + 1 till 2 weeks, 52

N/A

Abate et al.65

Italy

1996 to 1997

86

Standard Long GnRH Agonist

PLACEBO (1) vs IMP (6)

T1: placebo, 43

T6: 17-OHPc, IM, 50 mg, OPU + 1 till 2 weeks, 43

N/A

N/A

Aboulghar et al.66

Egypt

2011 to 2012

446

Standard Long GnRH Agonist

VP (3) vs. VPSCGNRH (14)

T3: Prontogest, PV, 600 mg, OPU till 2 weeks

T14: Decapeptyl, SC; 0.1 mg OD, OPU till 2 weeks; Prontogest, PV, 600 mg, OPU till 2 weeks

N/A

N/A

Aghsa et al.67

Iran

Not stated

147

Standard Short GnRH antagonist

VP (3) vs. PRP (16)

T3:Cyclogest, PV,800 mg, OPU till 6 weeks

T16: Cyclogest, PR,800 mg, OPU till 6 weeks

N/A

N/A

Ata et al.68

Turkey

2006 to 2007

570

Standard Long GnRH agonist protocol

VP (3) vs. VPSCGNRH (14)

T3: Crinone 8%, PV, 90 mg, OPU till 10 weeks, 285

T14: Decapeptyl, SC, 0.1 mg, six days after ICSI and Crinone 8%, PV, 90 mg, OPU till 10 weeks, 285

N/A

N/A

Baker et al.69

USA

2009–2011

800

GnRH agonist (long and flare protocols) and GnRH antagonist

SCP (2) vs. VP (3)

T2: Prolutex, SC, 25 mg, OPU till 12 weeks, 400

T3: Endometrin, PV, 200 mg, OPU till 12 weeks, 400

N/A

N/A

Ganesh et al.70

India

Not stated

904

Standard Long GnRH Agonist

VP (3) vs OP(10)

T3: Crinone 8%, PV, 90 mg, OPU till 12 weeks, 482

T10: Duphaston, O, 20 mg, OPU till 12 weeks, 422

N/A

N/A

Golan et al.71

Israel

Not stated

56

Ultrashort GnRH agonist protocol

IMP (T6) vs. IMHCG (T9)

T6: Progesterone, IM, 100 mg, from ET till 2 weeks, 26

T9: HCG, IM, 1000 IU or 2500 IU, from ET every 3 days for 2 weeks, 30

N/A

N/A

Inamdar et al.72

India

2010 to 2011

426

long GnRH agonist protocol

IMVP (T4) vs. IMVPSCGNRH (T19)

T4: Micronized progesterone, PV, 800 mg followed by progesterone, IM, 100 mg, OPU till 10 weeks, 213

T19: Micronized progesterone, PV, 800 mg followed by progesterone, IM, 100 mg, OPU till 10 weeks + Lupride 1 mg 6th, 7th and 8th days after OPU

N/A

N/A

Lockwood et al.73

Europe

2009 to 2010

683

GnRH agonist and GnRH antagonist

SCP (2) vs. VP (3)

T2:Prolutex, SC, 25 mg, OPU till 8 weeks, 339

T3: Crinone 8%, PV, 90 mg, OPU till 8 weeks, 344

N/A

N/A

Martinez et al.74

Spain

1996

310

Standard Long GnRH Agonist

VP (3) vs. IMHCG (T9)

T3:Utrogestan, PV, 300 mg, ET till 10 days,168

T9:HCG, IM, 2500 IU on 2,4,6, ET till 6 days, 142

N/A

N/A

Patki et al.75

India

2004 to 2005

675

Standard Long GnRH Agonist

VP (3) vs. OP (T10)

T3: Utrogestan, PV, 600 mg, OPU till 10 weeks, 309

T10: Dydrogesterone, O, 30 mg, OPU till 10 weeks, 150

N/A

N/A

Stadtmauer et al.76

USA

2008 to 2009

1297

long GnRH agonist protocol

VP (3)

T3: Ring/ Gel, PV, 11 mg (ring), 90 mg(gel), OPU + 1 till 10 weeks, 1297

N/A

N/A

N/A

Tesarik et al.77

Spain

2003 to 2005

572

Long GnRH agonist and GnRH antagonist protocol

VPOE (T5) vs. VPOESCGNRH (T15)

T5:Utrogestan, PV, 400 mg OPU till 17 days and Progynova, O, 4 mg, OPU till 17 days, 286

T15:Utrogestan, PV, 400 mg, OPU till 17 days and Progynova, O, 4 mg, OPU till 17 days and triptorelin, 0.1 mg, 6 days after ICSI, 286

N/A

N/A

Tournaye et al.78

Multicountry

2013 to 2016

974

Not stated

VP (3) VS OP (T10)

T3:Utrogestan, PV, 600 mg, OPU till 12 weeks, 477

T10:Dydrogesteron, O, 30 mg, OPU till 12 weeks, 497

N/A

N/A

Michnova et al.79

Czech Republic

Not stated

58

Long GnRH agonist and GnRH antagonist protocol

VP (3)

T3:Utrogestan, PV, 600 mg, OPU till 12 weeks, 477

N/A

N/A

N/A

Elgindy et al.80

Egypt

2015 to 2016

190

Standard Short GnRH antagonist

VPOE (5) vs. IMPOE (8)

T3:Endometrin, PV, 300 mg, OPU to 8 week and Estradiol valearate, O, 6 mg, OPU to 8 week, 95

T8: Prontogest IM, 100 mg, OPU till 8 weeks and Estradiol valereate, O, 6 mg, OPU till 8 weeks, 95

N/A

N/A

Yang et al.81

China

2015 to 2017

983

Long GnRH agonist and GnRH antagonist protocol

VP (3) VS. OP(10)

T3:Crinone 8%, PV, 90 mg/180 mg, OPU till 12 week, 489

T10: Duphaston, O, 30 mg, OPU till 12 week, 494

N/A

N/A

Tomic et al.82

Croatia

2010 to 2013

853

Standard Long GnRH Agonist

VP (3) VS. OP(10)

T3: Crinone 8%, PV, 90 mg/180 mg, OPU till 10 week, 416

T10: Duphaston, O, 20 mg, OPU till 10 week, 415

N/A

N/A

Gizzo et al.83

Italy

2010 to 2013

360

Standard Long GnRH Agonist (50%) ; Standard Short GnRH antagonist (25%); Short agonist (25%)

VP (3) VS. IMVP (4) VS. IMPVPOE (12)

T3:Progesterone, PV, 400 mg, OPU + 1 till ?12 weeks, 120

T4: Progesterone IM, 100 mg, OPU + 1 till 12 week and Brand unknown, PV, 600 mg, OPU + 1 till 12 week, 120

T12:Progesterone IM, 100 mg, OPU + 1 till 12 week and Brand unknown, PV, 600 mg, OPU + 1 till 12 week + valerate E2, O, 4 mg, OPU + 1 till 12 week; 120

N/A

Kutlusoy et al.84

Turkey

2008 to 2009

60

Standard Long GnRH Agonist or Standard Short GnRH antagonist

VP (3) VS. VPOE (5)

T3:Crinone 8%, PV, 90 mg, OPU till 10 week, 33

T5:Crinone 8%, PV, 90 mg, OPU till 10 week, and Estrofem, O, 2 mg, OPU to 10 weeks, 27

N/A

N/A

Ozer et al.85

Turkey

2019

134

Not stated

VP (3) VS. OP(10)

T3:Crinone 8%, PV, 90 mg, OPU till 12 week, 67

T10:Duphaston, O, 30 mg, OPU till 12 weeks, 67

N/A

N/A

Saharkhiz et al.86

Iran

2014 to 2015

210

Standard Long GnRH Agonist; Standard Short GnRH antagonist

VP (3) VS. OP(10)

T3:Cyclogest, PV, 800 mg, OPU till 12 weeks, 114

T10:Duphaston, O, 40 mg, OPU till 12 weeks, 96

N/A

N/A

Horowitz et al.87

Israel

2012 to 2018

59

Standard Long GnRH Agonist (34%); Standard Short GnRH antagonist (66%)

PLACEBO (T1) vs. VP (3)

T1: placebo, 43

T3:Endometrin, PV, 200 mg, OPU till 12 week , 31

N/A

N/A

Belaisch-Allart et al.88

France

1985 to 1986

286

clomiphene + and HMG , pure FSH, Programmed cycles

VP (3) VS. OP(10)

T1: placebo, 145

T10:Duphaston, O, Not stated, OPU till 3 weeks, 141

N/A

N/A

Chi et al.89

China

Not stated

1058

Standard Short GnRH antagonist

VP (3) VS. IMP (T6)

T3:Crinone 8%, PV, 90 mg, OPU till 6 week, 527

T6: Progesterone, IM, 60 mg, from ET till 6 weeks, 531

N/A

N/A

Fusi et al.90

Italy

2013 to 2015

1344

Standard Short GnRH antagonist

VP (3) VS. VPSCGNRH (T14)

T3:Cyclogest, PV, 600 mg, OPU till 12 weeks, 241

T14: Triptorelin, SC, 0.1 mg, from day of ET and every other day for 5 doses and Cyclogest, PV, 600 mg, OPU till NS weeks,507

N/A

N/A

Gorkemli et al.91

Turkey

2001 to 2003

144

Standard Long GnRH Agonist (100%)

VP (3) vs. VPPE (7)

T3:Progestan , PV, 600 mg, OPU till 10 weeks, 74

T7: Progestan, PV, 600 mg, OPU till 8 week and Estraderm T, Patch, 100 mcg, OPU till 10 week, 70

N/A

N/A

Ibrahem et al.92

Egypt

2016 to 2019

564

Standard Long GnRH Agonist (100%)

VP (3) vs OP (10)

T3:Prontogest , PV, 800 mg, OPU till 14 weeks, 280

T10:Duphaston, O, 30 mg, OPU till 12 weeks, 284

N/A

N/A

Kapur et al.93

India

Not stated

150

Standard Long GnRH Agonist (100%)

VP (3) vs VPOE (5)

T3:Micronized progesterone, PV, 800 mg, ET till 14 weeks, 75

T5:Micronized progesterone, PV, 800 mg, ET till 14 weeks + Estradiol valerate, O, 4 mg, ET till 14 weeks, 75

N/A

N/A

Khrouf et al.94

Tunisia

Not stated

126

Standard Long GnRH Agonist (73%); Standard Short GnRH antagonist (27%)

VP (3) vs PRP (16)

T3:Cyclogest , PV, 600 mg, ET till 14 weeks, 68

T16:Cyclogest , PR, 600 mg, ET till 14 weeks, 58

N/A

N/A

Kwon et al.95

Korea

Not stated

110

tandard Short GnRH antagonist

VP (3) vs VPOE (5)

T3:Crinone 8%, PV, 90 mg, OPU till 10 week, 55

T5:Micronized progesterone, PV, 800 mg, OPU till 10 weeks + Estradiol valerate, O, 4 mg, OPU till 10 weeks, 55

N/A

N/A

Mele et al.96

Italy

2017

130

Standard Long GnRH Agonist

SCP (T2) vs IMP (T6)

T2:Prolutex, SC, 25 mg, OPU till NS weeks, 65

T6: Progesterone, IM,33 mg from OPU and 50 mg, from ET till NS weeks, 65

N/A

N/A

Zargar et al.97

Iran

2014 to 2015

612

Standard Long GnRH Agonist (NS%); Standard Short GnRH antagonist (NS%)

VP (T3) vs IMP (T6) vs. OP (10)

T3:Prontogest , PV, 800 mg, ET till 12 weeks, 200

T6: Progesterone, IM, 100 mg, from ET till 12 weeks, 200

T10:Duphaston, O, 30 mg, ET till 12 weeks, 212

N/A

Pirard et al.98

Belgium

Not stated

53

Standard Short GnRH antagonist

VP (T3) vs. INGNRH ( T22)

T3:NS,600 mg, PV, OPU till 12 weeks, 18

T22:Buserelin, 200mcg, , followed by 100 μg IN buserelin TDS for luteal support starting the next day of ovulation trigger, 35

N/A

N/A

Var et al.99

Turkey

2007 to 2008

288

Standard Long GnRH Agonist

VP (T3) vs. VPOE (T5) vs. IMHCG (T9)

T3:Crinone 8%, PV, 12 mg, ET till 10 week, 97

T5:Crinone 8%, PV, 12 mg, ET till 10 week + Estrofem, O, 4 mg, OPU till 10 weeks, 96

T9: hCG, ,500 IU of hCG IM on the ET day, as well as 3 and 6 days, 95

N/A

Humaidan100

Denmark

2014 to 2019

250

Standard Short GnRH antagonist

VP (T3) vs. SCHCG (T17)

T3:Lutinus, Dose not stated, TDS, OPU till 2 weeks, 125

T17: Two groups 1500 IU at OPU and second dose 1000 IU at OPU + 4; Second group 1000 IU HCG at OPU and 500 IU at OPU + 4,125

N/A

N/A

  1. Patient sample, ovarian stimulation protocol, luteal support comparison and regimen.
  2. Placebo, no exposure; SCP, Subcutaneous progesterone; VP, vaginal progesterone; IMP + VP, intramuscular progesterone and vaginal progesterone; VP + OE, vaginal progesterone and oral estradiol; IMP, intramuscular progesterone; VP + PatchE, vaginal progesterone and patch oestrogen; IMP + OE, intramuscular progesterone and oral estradiol; IMHCG, intramuscular hCG; SCP + VP, Intranasal GnRH-a; OP, oral progesterone; IMP + IME, intramuscular progesterone and intramuscular estradiol; IMP + VP + OE, Intramuscular progesterone, vaginal progesterone and oral estradiol; IMP + VE, Intramuscular progesterone and vaginal estradiol; VP + SCGNRH-a, Vaginal progesterone and subcutaneous GNRH agonist (GNRH-a); VP + OE + SCGNRH-a, Vaginal progesterone, oral estradiol and subcutaneous GNRH-a; RP, Rectal progesterone; SCHCG, subcutaneous HCG; VP + DHEA, vaginal progesterone and oral DHEA; IMP + VP + SCGNRH-a, Intramuscular progesterone, vaginal progesterone and subcutaneous GNRH-a; OP + VP, oral progesterone and vaginal progesterone.
Back to article page